Physician profile
Anthony Johnson
NPI 1104186246
$5,688.15
in general payments reported to CMS, 2019-2025
39 companies · $658 in 2025
The $658 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,452 · 2020: $445 · 2021: $828 · 2022: $611 · 2023: $1,055 · 2024: $639 · 2025: $658.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,352.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,352.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $742.41 | 2019-2025 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $622.41 | 2019-2024 | Xarelto |
| Pfizer INC. | $463.30 | 2019-2025 | |
| Novo Nordisk INC | $450.33 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $400.11 | 2019-2025 | |
| Paratek Pharmaceuticals, INC. | $315.66 | 2021-2025 | Nuzyra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $261.85 | 2019-2023 | Jardiance |
| Merck Sharp & Dohme LLC | $236.80 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $222.63 | 2022-2025 | Rexulti |
| Lilly USA, LLC | $207.39 | 2019-2025 | Zepbound, Amyvid, Mounjaro |
| Sanofi-Aventis U.S. LLC | $199.01 | 2019-2025 | |
| Axsome Therapeutics, INC. | $173.00 | 2023-2025 | Auvelity |
| Amgen INC. | $127.83 | 2019-2024 | Repatha, Otezla |
| Kowa Pharmaceuticals America, INC. | $115.27 | 2019 | |
| Novartis Pharmaceuticals Corporation | $109.39 | 2022-2024 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.